The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small phase 2 trials. OBJECTIVE: To compare efficacy and safety of HSCT vs 12 successive monthly intravenous pulses of cyclophosphamide. DESIGN, SETTING, AND PARTICIPANTS: The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a phase 3, multicenter, randomized (1:1), open-label, parallel-group, clinical trial conducted in 10 countries at 29 centers with access to a European Group for Blood and Marrow Transplantation-registered transplant facility. From March 2001 to October 2009, 156 patients with early diffuse cutaneous systemic sclerosis were recruited and followed up until October 31, 2013. INTERVENTIONS: HSCT vs intravenous pulse cyclophosphamide. MAIN OUTCOMES AND MEASURES: The primary end point was event-free survival, defined as time from randomization until the occurrence of death or persistent major organ failure. RESULTS: A total of 156 patients were randomly assigned to receive HSCT (n = 79) or cyclophosphamide (n = 77). During a median follow-up of 5.8 years, 53 events occurred: 22 in the HSCT group (19 deaths and 3 irreversible organ failures) and 31 in the control group (23 deaths and 8 irreversible organ failures). During the first year, there were more events in the HSCT group (13 events [16.5%], including 8 treatment-related deaths) than in the control group (8 events [10.4%], with no treatment-related deaths). At 2 years, 14 events (17.7%) had occurred cumulatively in the HSCT group vs 14 events (18.2%) in the control group; at 4 years, 15 events (19%) had occurred cumulatively in the HSCT group vs 20 events (26%) in the control group. Time-varying hazard ratios (modeled with treatment × time interaction) for event-free survival were 0.35 (95% CI, 0.16-0.74) at 2 years and 0.34 (95% CI, 0.16-0.74) at 4 years. CONCLUSIONS AND RELEVANCE: Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment. However, HCST conferred a significant long-term event-free survival benefit. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN54371254.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Burt, R. K., Shah, S. J., Dill, K., Grant, T., Gheorghiade, M., Schroeder, J., Craig, R., Hirano, I., Marshall, K., Ruderman, E., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60982-3 · Cited by 578
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
Chifflot, H., Fautrel, B., Sordet, C., et al. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.05.003 · Cited by 460
Farge, D., Labopin, M., Tyndall, A., Fassas, A., Mancardi, G. L., Van Laar, J., Ouyang, J., Kozak, T., Moore, J., Kotter, I., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.013458 · Cited by 364
Self-citation(PDWP), O. B. O. T. E. A. D. W. P. (. A. P. D. W. P., Snowden, J. A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., Denton, C., Hawkey, C., Labopin, M., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.185 · Cited by 328
Self-citationBinks, M., Passweg, J. R., Furst, D., McSweeney, P., Sullivan, K., Besenthal, C., Finke, J., Peter, H. H., van Laar, J., Breedveld, F. C., et al. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.6.577 · Cited by 288
Self-citationNash, R. A., McSweeney, P. A., Crofford, L. J., Abidi, M., Chen, C.-S., Godwin, J. D., Gooley, T. A., Holmberg, L., Henstorf, G., LeMaistre, C. F., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072389 · Cited by 265
Domsic, R. T., Rodriguez-Reyna, T., Lucas, M., Fertig, N., & Medsger, T. A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.127621 · Cited by 257
Farge, D., Passweg, J., van Laar, J. M., Marjanovic, Z., Besenthal, C., Finke, J., Peter, H. H., Breedveld, F. C., Fibbe, W. E., Black, C., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011205 · Cited by 251
Self-citationVonk, M. C., Marjanovic, Z., van den Hoogen, F. H. J., Zohar, S., Schattenberg, A. V. M. B., Fibbe, W. E., Larghero, J., Gluckman, E., Preijers, F. W. M. B., van Dijk, A. P. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071464 · Cited by 169
Self-citationSkin involvement in scleroderma--where histological and clinical scores meet
Verrecchia, F., Laboureau, J., VEROLA, O., Roos, N., Porcher, R., Bruneval, P., Daneshpouy, M. E., TIEV, K. P., Michel, L., Mauviel, A., et al. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kel451 · Cited by 157
Self-citationMinimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study
Khanna, D., Furst, D. E., Hays, R. D., Park, G. S., Wong, W. K., Seibold, J. R., Mayes, M. D., White, B., Wigley, F. F., Weisman, M. H., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.050187 · Cited by 154
Self-citationHigh prevalence of occult left heart disease in scleroderma-pulmonary hypertension
Fox, B. D., Shimony, A., Langleben, D., Hirsch, A., Rudski, L., Schlesinger, R., Eisenberg, M. J., Joyal, D., Hudson, M., Boutet, K., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00091212 · Cited by 152
Cigarette smoking in patients with systemic sclerosis.
Hudson, M., Lo, E., Lu, Y., Hercz, D., Baron, M., & Steele, R. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30071 · Cited by 91
Pasquini, M. C., Voltarelli, J. C., Atkins, H. L., Hamerschlak, N., Zhong, X., Ahn, K. W., Sullivan, K. M., Carrum, G., Andrey, J., Bredeson, C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.06.003 · Cited by 70
Ehlers, S. L., Gastineau, D. A., Patten, C. A., Decker, P. A., Rausch, S., Cerhan, J. R., Hogan, W. J., Ebbert, J. O., & Porrata, L. F. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.113 · Cited by 50
Cigarette Smoking and Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
Tran, B. T., Halperin, A. C., & Chien, J. W. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.10.032 · Cited by 31
Cited by
Denton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Update of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Self-citationAllanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C. P., & Varga, J. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.2 · Cited by 876
Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Self-citationVolkmann, E. R., Andréasson, K., & Smith, V. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01692-0 · Cited by 616
Metadata
- Authors
- van Laar, J. M., Farge, D., Sont, J. K., Naraghi, K., Marjanovic, Z., Larghero, J., Schuerwegh, A. J., Marijt, E. W. A., Vonk, M. C., Schattenberg, A. V., Matucci-Cerinic, M., Voskuyl, A. E., van de Loosdrecht, A. A., Daikeler, T., Kötter, I., Schmalzing, M., Martin, T., Lioure, B., Weiner, S. M., Kreuter, A., Deligny, C., Durand, J.-M., Emery, P., Machold, K. P., Sarrot-Reynauld, F., Warnatz, K., Adoue, D. F. P., Constans, J., Tony, H.-P., Del Papa, N., Fassas, A., Himsel, A., Launay, D., Lo Monaco, A., Philippe, P., Quéré, I., Rich, É., Westhovens, R., Griffiths, B., Saccardi, R., van den Hoogen, F. H., Fibbe, W. E., Socié, G., Gratwohl, A., & Tyndall, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-06-25
- Volume
- 311
- Issue
- 24
- Pages
- 2490
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2041443103
- Cited by
- 766
- References
- 17
- FWCI
- 42.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.